CD274 and neoplasm: Currently, immunomodulators, such as those targeting the PD‐1/PD‐L1 pathway, in addition to first‐line chemotherapy play an effective role in the treatment of some TNBC patients, but these therapies have poor efficacy in other patients due to the complexity of the tumor immune microenvironment (TIME) in TNBC.2, 3, 4, 5